Keenova Therapeutics plc: net property, plant and equipment
Net property, plant and equipment for Keenova Therapeutics plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Keenova Therapeutics plc financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-09-28 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 185,400,000 | USD | 2026-04-15 | 10-K · 0001628280-26-025238 |
| At date | 2024-12-27 | 117,200,000 | USD | 2026-04-15 | 10-K · 0001628280-26-025238 |
| At date | 2023-12-29 | 321,700,000 | USD | 2025-03-13 | 10-K · 0001567892-25-000010 |
| At date | 2022-12-30 | 457,600,000 | USD | 2024-03-26 | 10-K · 0001567892-24-000008 |
| At date | 2021-12-31 | 776,000,000 | USD | 2023-03-03 | 10-K · 0001567892-23-000014 |
| At date | 2020-12-25 | 833,100,000 | USD | 2022-03-15 | 10-K · 0001567892-22-000007 |
| At date | 2019-12-27 | 896,500,000 | USD | 2021-03-10 | 10-K · 0001567892-21-000011 |
| At date | 2018-12-28 | 982,000,000 | USD | 2020-02-26 | 10-K · 0001567892-20-000005 |
| At date | 2017-12-29 | 966,800,000 | USD | 2019-02-26 | 10-K · 0001567892-19-000009 |
| At date | 2016-12-30 | 881,500,000 | USD | 2018-02-27 | 10-K · 0001567892-18-000010 |
| At date | 2016-09-30 | 844,000,000 | USD | 2016-11-29 | 10-K · 0001567892-16-000098 |
| At date | 2015-09-25 | 793,000,000 | USD | 2016-11-29 | 10-K · 0001567892-16-000098 |
| At date | 2014-09-26 | 886,800,000 | USD | 2015-11-24 | 10-K · 0001567892-15-000047 |
| At date | 2013-09-27 | 997,400,000 | USD | 2014-11-25 | 10-K · 0001567892-14-000040 |
| At date | 2012-09-28 | 945,200,000 | USD | 2013-12-13 | 10-K · 0001567892-13-000029 |
Related financial histories
- Keenova Therapeutics plc: total assets
- Keenova Therapeutics plc: total liabilities
- Keenova Therapeutics plc: stockholders equity
- Keenova Therapeutics plc: cash and cash equivalents
- Keenova Therapeutics plc: net income or loss
- Keenova Therapeutics plc: operating cash flow
- Keenova Therapeutics plc: capital expenditure payments
- Keenova Therapeutics plc: financing cash flow
- Keenova Therapeutics plc: investing cash flow
- Keenova Therapeutics plc: retained earnings or deficit
- Keenova Therapeutics plc: basic weighted-average shares
- Keenova Therapeutics plc: diluted weighted-average shares
- Keenova Therapeutics plc: basic earnings per share
- Keenova Therapeutics plc: diluted earnings per share
- Keenova Therapeutics plc: income tax expense or benefit
- Keenova Therapeutics plc: share-based compensation expense
- Keenova Therapeutics plc: operating income or loss
- Keenova Therapeutics plc: current assets
- Keenova Therapeutics plc: interest expense
- Keenova Therapeutics plc: current liabilities
- Keenova Therapeutics plc: current accounts payable
- Keenova Therapeutics plc: goodwill carrying amount
- Keenova Therapeutics plc: net current accounts receivable
- Keenova Therapeutics plc: common-stock repurchase payments
- Keenova Therapeutics plc: net inventory
- Keenova Therapeutics plc: gross profit
- Keenova Therapeutics plc: selling, general and administrative expense
- Keenova Therapeutics plc: research and development expense
- Keenova Therapeutics plc: common shares outstanding
- Keenova Therapeutics plc: cash including restricted cash
- Keenova Therapeutics plc: additional paid-in capital
- Keenova Therapeutics plc: accumulated other comprehensive income or loss
- Keenova Therapeutics plc: operating lease right-of-use asset
- Keenova Therapeutics plc: operating lease liability
- Keenova Therapeutics plc: gross property, plant and equipment
- Keenova Therapeutics plc: accumulated depreciation on property, plant and equipment
- Keenova Therapeutics plc: net intangible assets excluding goodwill
- Keenova Therapeutics plc: other noncurrent assets
- Keenova Therapeutics plc: other noncurrent liabilities
- Keenova Therapeutics plc: prepaid expenses and other current assets
- Keenova Therapeutics plc: current contract liabilities
- Keenova Therapeutics plc: net deferred tax liabilities
- Keenova Therapeutics plc: pre-tax income or loss from continuing operations
- Keenova Therapeutics plc: comprehensive income or loss
- Keenova Therapeutics plc: net income available to common stockholders
- Keenova Therapeutics plc: depreciation expense
- Keenova Therapeutics plc: depreciation, depletion and amortization
- Keenova Therapeutics plc: amortization of intangible assets
- Keenova Therapeutics plc: nonoperating interest expense
- Keenova Therapeutics plc: other nonoperating income or expense
- Keenova Therapeutics plc: current income tax expense or benefit
- Keenova Therapeutics plc: deferred income tax expense or benefit
- Keenova Therapeutics plc: interest paid, net
- Keenova Therapeutics plc: income taxes paid, net
- Keenova Therapeutics plc: operating lease payments
- Keenova Therapeutics plc: change in accounts receivable
- Keenova Therapeutics plc: change in inventories
- Keenova Therapeutics plc: change in accounts payable
Inspect the source
- Entity
- Keenova Therapeutics plc / CIK 0001567892
- Captured
- 2026-09-21T17:20:47.960Z
- SEC response SHA-256
1bf3b597047f68db7ed08f461596630f6c4d06bb520c701b2d0069468ac4ed83
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001567892.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))